Sustained release of silibinin-loaded chitosan nanoparticle induced apoptosis in glioma cells

被引:33
作者
Alipour, Maryam [1 ,3 ,4 ]
Bigdeli, Mohammad Reza [1 ]
Aligholi, Hadi [2 ]
Rasoulian, Bahram [3 ,4 ]
Khaksarian, Mojtaba [3 ,4 ]
机构
[1] Shahid Beheshti Univ, Fac Life Sci & Biotechnol, Tehran, Iran
[2] Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Neurosci, Shiraz, Iran
[3] Lorestan Univ Med Sci, Razi Herbal Med Res Ctr, Khorramabad, Iran
[4] Lorestan Univ Med Sci, Dept Physiol, Khorramabad, Iran
关键词
apoptosis; chitosan; Glioma; nanoparticle; silibinin; DELIVERY-SYSTEMS; TUMOR-GROWTH; CYCLE ARREST; CANCER; DRUG; ANTICANCER; GLIOBLASTOMA; PROLIFERATION; SUPPRESSION; INHIBITION;
D O I
10.1002/jbm.a.36827
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
In this study, a chitosan nanoparticle formulation was synthesized for loading silibinin as a sustained-release drug system to evaluate its effects on apoptosis in C6 glioma cells. This synthesized nanoparticle was analyzed by measurement methods including Fourier transform infrared (FTIR), field emission-scanning electron microscopy (FE-SEM), dynamic light scattering (DLS), X-ray diffraction (XRD), and differential scanning calorimetry (DSC). The formation and amorphization of nanoparticle were confirmed by FTIR and XRD analysis, respectively. The mean diameter of silibinin-loaded chitosan nanoparticles (SCNP) was 50 +/- 7 and 188.6 +/- 0.17 nm by using FE-SEM and DLS, respectively. In addition, the positive zeta potential of nanoparticles was +11.5. Rhodamine-conjugated SCNP analysis showed the internalization of silibinin to C6 glioma cells. The cytotoxicity assay indicated that the nanoformulation of silibinin was toxic to C6 glioma cells. Although SCNP significantly increased the expression of the both apoptotic genes in C6 cells, Bax and caspase3, it did not have any significant effect on the level of the antiapoptotic gene, Bcl2. In contrast, SCNP did not have any toxic effect on H9C2 cells. In conclusion, the results of the current study indicated that SCNP can be considered as a sustained-release drug system for future cell-based therapeutic strategies.
引用
收藏
页码:458 / 469
页数:12
相关论文
共 49 条
[1]   Chitosan-based formulations of drugs, imaging agents and biotherapeutics Preface [J].
Amidi, Maryam ;
Hennink, Wim E. .
ADVANCED DRUG DELIVERY REVIEWS, 2010, 62 (01) :1-2
[2]  
[Anonymous], 2014, AM J PHARM SCI
[3]   Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? [J].
Asghar, Uzma ;
Meyer, Tim .
JOURNAL OF HEPATOLOGY, 2012, 56 (03) :686-695
[4]   Synthesis and characterization of PLGA nanoparticles [J].
Astete, Carlos E. ;
Sabliov, Cristina M. .
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 2006, 17 (03) :247-289
[5]   Anticancer and Anti-Inflammatory Properties of Chitin and Chitosan Oligosaccharides [J].
Azuma, Kazuo ;
Osaki, Tomohiro ;
Minami, Saburo ;
Okamoto, Yoshiharu .
JOURNAL OF FUNCTIONAL BIOMATERIALS, 2015, 6 (01) :33-49
[6]   Chitosan-based drug delivery systems [J].
Bernkop-Schnuerch, Andreas ;
Duennhaupt, Sarah .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 81 (03) :463-469
[7]   Enhancement of radiation-induced oxidative stress and cytotoxicity in tumor cells by ellagic acid [J].
Bhosle, SM ;
Huilgol, NG ;
Mishra, KP .
CLINICA CHIMICA ACTA, 2005, 359 (1-2) :89-100
[8]   Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2 [J].
Chang, Chia-Ming ;
Chang, Pei-Ying ;
Tu, Ming-Gene ;
Lu, Chi-Cheng ;
Kuo, Sheng-Chu ;
Amagaya, Sakae ;
Lee, Chao-Ying ;
Ja, Hui-Yu ;
Chen, Michael Yuanchien ;
Yang, Jai-Sing .
ONCOLOGY REPORTS, 2012, 28 (05) :1799-1807
[9]   Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules [J].
Chen, Mei-Chin ;
Mi, Fwu-Long ;
Liao, Zi-Xian ;
Hsiao, Chun-Wen ;
Sonaje, Kiran ;
Chung, Min-Fan ;
Hsu, Li-Wen ;
Sung, Hsing-Wen .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (06) :865-879
[10]  
Chien Y. W., 1983, NOVEL DRUG DELIVERY, P648